| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/17/2001 | EP1144640A2 Nucleic acids and proteins from streptococcus pneumoniae |
| 10/17/2001 | EP1144633A1 Polypeptide |
| 10/17/2001 | EP1144630A2 Human cell signaling proteins (csig) |
| 10/17/2001 | EP1144628A2 Human vanilloid receptor gene |
| 10/17/2001 | EP1144617A2 Cancer-associated proteins |
| 10/17/2001 | EP1144614A2 33 human secreted proteins |
| 10/17/2001 | EP1144605A2 Dimethylarginine dimethylaminohydrolases |
| 10/17/2001 | EP1144598A2 Human homologues of proteins regulated by circadian rhythms |
| 10/17/2001 | EP1144451A2 Method of modulating cell differentiation or neoplastic trnasformation by altering cadherin-11 expression or function |
| 10/17/2001 | EP1144450A1 Mammalian alpha-helical protein - 12 |
| 10/17/2001 | EP1144439A2 Hematopoietic regulatory factors and methods of use thereof |
| 10/17/2001 | EP1144423A1 Bis-terpyridine-platinum(ii) complexes |
| 10/17/2001 | EP1144420A1 Sulfated phosphatidylinositols, their preparation and use |
| 10/17/2001 | EP1144394A1 1-heterocycle substituted diarylamines |
| 10/17/2001 | EP1144372A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 10/17/2001 | EP1144370A2 Thyroid receptor ligands |
| 10/17/2001 | EP1144362A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 10/17/2001 | EP1144050A2 Binding partners for 5-ht5-receptors for the treatment of migraine |
| 10/17/2001 | EP1144008A1 Modulation of systemic memory t cell trafficking |
| 10/17/2001 | EP1144006A2 Synergistic inhibition of hiv-1 fusion and attachment, compositions and antibodies thereto |
| 10/17/2001 | EP1144003A1 Methods and devices for delivery of agents to breast milk ducts |
| 10/17/2001 | EP1144000A1 New dialysis method |
| 10/17/2001 | EP1143998A2 Treatment of hypertension |
| 10/17/2001 | EP1143997A1 Tumor necrosis factor antagonists and their use in endometriosis |
| 10/17/2001 | EP1143996A2 Method of treating chronic cardiac disease |
| 10/17/2001 | EP1143994A2 Use of apoptosis inducing agents in the treatment of (auto)immune diseases |
| 10/17/2001 | EP1143993A1 Method of suppressing ongoing acute allograff rejection |
| 10/17/2001 | EP1143990A2 Pharmaceutical compostions comprising peg-asparaginase for the treatment of hiv infections |
| 10/17/2001 | EP1143981A1 Treatment and prevention of hiv and other viral infections |
| 10/17/2001 | EP1143978A2 Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding |
| 10/17/2001 | EP1143976A2 Beta-d-2', 3' -didehydro-2', 3' -dideoxy-5-fluorocytidine for use in the treatment of hiv infections |
| 10/17/2001 | EP1143975A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 10/17/2001 | EP1143973A2 Compositions having improved stability |
| 10/17/2001 | EP1143965A1 Carbocyclic potassium channel inhibitors |
| 10/17/2001 | EP1143961A2 Regulators of the ptc or smoothened pathway, compositions and uses related thereto |
| 10/17/2001 | EP1143958A2 Pharmaceutical composition and use of rnsaid for treating inflammation |
| 10/17/2001 | EP1143957A2 Treatment of arthritis with mek inhibitors |
| 10/17/2001 | EP1143956A2 Compositions and methods for the treatment of anorectal disorders |
| 10/17/2001 | EP1143955A2 A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES |
| 10/17/2001 | EP1143953A2 Method of inhibiting angiogenesis |
| 10/17/2001 | EP1143952A2 Method and composition for treating and preventing tuberculosis |
| 10/17/2001 | EP1143948A2 Liver-selective glucocorticoid antagonist for treating diabetes |
| 10/17/2001 | EP1143946A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 10/17/2001 | EP1143943A2 P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
| 10/17/2001 | EP1143942A2 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
| 10/17/2001 | EP1143941A2 Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections |
| 10/17/2001 | EP1143936A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN $g(a)-ANTAGONIST |
| 10/17/2001 | EP1143935A2 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 10/17/2001 | EP1143933A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 10/17/2001 | EP1143931A1 Pulmonary drug delivery |
| 10/17/2001 | EP1143927A2 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants |
| 10/17/2001 | EP1143920A1 Oil-in-water emulsion comprising a micronised biologically active agent and an appropriate emulsifier system |
| 10/17/2001 | EP1143896A1 Methods of hydrating mucosal surfaces |
| 10/17/2001 | EP1143806A2 Method for increasing pet activity |
| 10/17/2001 | EP1143794A1 Lubrication composition |
| 10/17/2001 | EP0833818B1 3-acylindoles as cb2 receptor agonists |
| 10/17/2001 | EP0776201B1 Treating anxiety |
| 10/17/2001 | CN1318103A Nucleic acids and proteins from streptococcus pneumoniae |
| 10/17/2001 | CN1318058A 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CRTP inhibitors |
| 10/17/2001 | CN1318057A 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoliines as CETP inhibitors |
| 10/17/2001 | CN1318056A Pyridinum derivatives for management of aging-related and diabetic vascular complications, process for their prepn. and therepeutic uses thereof |
| 10/17/2001 | CN1317979A Serotonergic 5HT2 agonists for treating glaucoma |
| 10/17/2001 | CN1317977A Dry powder active agent pulmonary delivery |
| 10/17/2001 | CN1317970A Method for treating atherosclerosis empolying ap2 inhibitor and combination |
| 10/17/2001 | CN1317966A Utilization of aryl (or heteroaryl) azolylcarbinol derivatives in prepn. of medicament for treating troubles mediated by excess of substance P |
| 10/17/2001 | CN1317965A Compounds having IgE affecting properties |
| 10/17/2001 | CN1317952A Improved method for targeted topial treatment of disease |
| 10/17/2001 | CN1073119C Method and compsns. for dry powder formulation of interferons |
| 10/17/2001 | CN1072930C Compsn. comrising tramadol material and non-steriodal anti-inflammatory drug |
| 10/16/2001 | USRE37410 Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| 10/16/2001 | US6303661 Orally administering inhibitor of dipeptidyl peptidase (dp iv) or of dipeptidyl peptidase iv-like activity |
| 10/16/2001 | US6303660 Enhanced anti-cancer agent delivery to solid tumors by primer compounds |
| 10/16/2001 | US6303645 Benzimidazole derivatives as modulators of IgE |
| 10/16/2001 | US6303644 Administering proton pump inhibitor or its salt in comination with antibacterial compound for therapy of bacterial disease which does not effect gastrointestinal tract |
| 10/16/2001 | US6303640 Administering oxazole or thiazole derivative compound for reducing side effects of diabetic therapy |
| 10/16/2001 | US6303637 For therapy of autoimmune disease, prophylaxis of resistance to transplantation or transplantation rejection of organs or tissues; suppressing immune system |
| 10/16/2001 | US6303636 Arylsulfonylamino hydroxamic acid derivatives |
| 10/16/2001 | US6303621 Method for treating cancers using a diiodo thyronine analogue having no significant hormonal activity and a vinca alkaloid and compositions comprising the same |
| 10/16/2001 | US6303611 For therapy of hyperalgesis |
| 10/16/2001 | US6303606 Use of selective antagonists of the α1B-adrenergic receptor for improvement of sexual dysfunction |
| 10/16/2001 | US6303588 Applying to portions of the skin of such patient which have abnormal skin cell metabolism bioactive agent comprising adenosine-5-triphosphate, quanosine-5-triphosphate and phosphinositedes and biologically acceptable carrier |
| 10/16/2001 | US6303585 Cross-linked polysaccharide drug carrier |
| 10/16/2001 | US6303580 Cyclitol Containing carbohydrates from human tissue which regulate lipogenic activity |
| 10/16/2001 | US6303572 Control of acidic gut syndrome |
| 10/16/2001 | US6303569 Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| 10/16/2001 | US6303334 Nucleotide sequences coding polypeptides for use in as a viricide and in gene therapy |
| 10/16/2001 | US6303333 Expression vector which codes polypeptides for the diagnosis and treatment of cancer, dietetics, inflammation, cardiovascular disorders, crohn's diseases, neuropathies and immune defects |
| 10/16/2001 | US6303321 Methods for diagnosing sepsis |
| 10/16/2001 | US6303319 Cell based assay for identifying sh2-domain-specific signal transducer antagonist |
| 10/16/2001 | US6303151 Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| 10/16/2001 | US6303141 Passive sustained release transdermal drug delivery system |
| 10/16/2001 | US6303121 Method of using human receptor protein 4-1BB |
| 10/16/2001 | US6303115 Screening methods using microbial strain pools |
| 10/16/2001 | US6303103 1,1,1,2-tetrafluoroethane as propellant; inhalants. |
| 10/16/2001 | CA2241464C Nisin in combination with glycerol monolaurate active against helicobacter |
| 10/14/2001 | CA2344183A1 Glycoprotein having inhibitory activity against helicobacter pylori colonization |
| 10/13/2001 | CA2343850A1 Synergistic effect of a sulfonylurea and/or non-sulfonylurea k+ atp channel blocker, and a phosphodiesterase 3 type inhibitor |
| 10/12/2001 | CA2335109A1 Cxcr4 agonist treatment of hematopoietic cells |
| 10/12/2001 | CA2318665A1 Method of treating onychomycosis |
| 10/11/2001 | WO2001075440A2 Schizophrenia related genes |